Cancer Genetics, Inc. (CGI) is a leader in drug discovery and preclinical oncology and immuno-oncology services enhancing the development of advanced therapies in precision medicine.
CGI is focused on extending its history of leading in the innovation of proprietary products and superior services through investments in unique technologies. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. We are actively pursuing strategic actions to further accelerate our growth in the field of precision medicine.
Cancer Genetics, Inc. was founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti. Built on a foundation of world-class scientific knowledge and IP in certain diagnostic products and preclinical drug discovery services, the company continues to build strong research collaborations with academic institutions and emerging life science companies.
In 2018 and 2019, CGI divested several prior acquisitions to generate significant cash and eliminate debt, allowing for a focus to specialize in conducting clinical trial studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings.
Meet the CGI Team
Learn more about how our team of world-class scientists and experienced management is helping to empower precision medicine.